Circulation, Vol 88, 1588-1601, Copyright © 1993 by American Heart Association
PW Serruys, W Klein, JP Tijssen, W Rutsch, GR Heyndrickx, H Emanuelsson, SG Ball, O Decoster, E Schroeder and H Liberman
BACKGROUND. Ketanserin is a serotonin S2-receptor antagonist that inhibits
the platelet activation and vasoconstriction induced by serotonin and also
inhibits the mitogenic effect of serotonin on vascular smooth muscle cells.
METHODS AND RESULTS. We conducted a randomized, double blind,
placebo-controlled trial to assess the effect of ketanserin in restenosis
prevention after percutaneous transluminal coronary angioplasty (PTCA).
Patients received either ketanserin (loading dose, 40 mg 1 hour before
PTCA; maintenance dose, 40 mg bid for 6 months) or matched placebo. In
addition, all patients received aspirin for 6 months. Coronary angiograms
before PTCA, after PTCA, and at 6 months were quantitatively analyzed. Six
hundred fifty-eight patients were entered into the intention-to-treat
analysis. The primary clinical end point of the study was the occurrence
between PTCA and 6 months of any one of the following: cardiac death,
myocardial infarction, the need for repeat angioplasty, or bypass surgery.
It also included the need for revascularization actuated by findings at
6-month follow-up angiography. The primary clinical end point was reached
by 92 (28%) patients in the ketanserin group and 104 (32%) in the placebo
group (RR, 0.89; 95% CI, 0.70, 1.13; P = .38). Quantitative angiography
after PTCA and at follow-up was available in 592 patients (ketanserin, 287;
control, 305). The mean difference in minimal lumen diameter between
post-PTCA and follow-up angiogram (primary angiographic end point) was 0.27
+/- 0.49 mm in the ketanserin group and 0.24 +/- 0.52 mm in the control
group (difference, 0.03 mm; 95% CI, -0.05, 0.11; P = .50). CONCLUSIONS.
Ketanserin at the dose administered in this trial failed to reduce the loss
in minimal lumen diameter during follow-up after PTCA and did not
significantly improve the clinical outcome.
ARTICLES
Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial
Catheterization Laboratory, Thoraxcenter, Rotterdam, The Netherlands.
This article has been cited by other articles:
 |
|
 |
|
  R. C. Becker, T. W. Meade, P. B. Berger, M. Ezekowitz, C. M. O'Connor, D. A. Vorchheimer, G. H. Guyatt, D. B. Mark, and R. A. Harrington The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 776S - 814S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Popma, P. Berger, E. M. Ohman, R. A. Harrington, C. Grines, and J. I. Weitz Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 576S - 599S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Le Blanche, M. Bonneau, M. Wassef, M.-T. Farres, L. Gabez, B. Aubert, M. Duriez, B. I. Levy, J.-M. Bigot, and F. Boudghene Histomorphometric Evaluation of 198Au Endovascular Brachytherapy in a Renal Artery Restenosis Model in Rabbits Am. J. Roentgenol., September 1, 2002; 179(3): 611 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mercado, E. Boersma, W. Wijns, B. J. Gersh, C. A. Morillo, V. de Valk, G.-A. van Es, D. E. Grobbee, and P. W. Serruys Clinical and quantitative coronary angiographic predictors of coronary restenosis: A comparative analysis from the balloon-to-stent era J. Am. Coll. Cardiol., September 1, 2001; 38(3): 645 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Smith Jr, J. T. Dove, A. K. Jacobs, J. Ward Kennedy, D. Kereiakes, M. J. Kern, R. E. Kuntz, J. J. Popma, H. V. Schaff, D. O. Williams, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2239 - 2239. [Full Text] [PDF]
|
|
|
|
 |
|
 M.Y Salame, S Verheye, I.R Crocker, N.A.F Chronos, K.A Robinson, and S.B King III Intracoronary radiation therapy Eur. Heart J., April 2, 2001; 22(8): 629 - 647. [PDF]
|
|
|
|
|
|
J. J. Popma, E. M. Ohman, J. Weitz, A. M. Lincoff, R. A. Harrington, and P. Berger Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention Chest, January 1, 2001; 119 (2009): 321S - 336S. [Full Text] [PDF]
|
|
|
|
|
|
M. Sabate, M. A. Costa, K. Kozuma, I. P. Kay, C. J. van der Wiel, V. Verin, W. Wijns, P. W. Serruys, and on behalf of the Dose Finding Study Group Methodological and clinical implications of the relocation of the minimal luminal diameter after intracoronary radiation therapy J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1536 - 1541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A G Violaris, A Thury, E Regar, R Melkert, and P W Serruys Influence of a history of smoking on short term (six month) clinical and angiographic outcome after successful coronary angioplasty Heart, September 1, 2000; 84(3): 299 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Vikenes, M. Farstad, and J. E. Nordrehaug Serotonin Is Associated with Coronary Artery Disease and Cardiac Events Circulation, August 3, 1999; 100(5): 483 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.W. Serruys, D.P. Foley, G. Jackson, H. Bonnier, C. Macaya, M. Vrolix, A. Branzi, J. Shepherd, H. Suryapranata, P.J. de Feyter, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: Final results of the fluvastatin angiographic restenosis (FLARE) trial Eur. Heart J., January 1, 1999; 20(1): 58 - 69. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Gershlick Endovascular manipulation to restrict restenosis Vascular Medicine, August 1, 1998; 3(3): 177 - 188. [Abstract] [PDF]
|
|
|
|
|
|
G. A. Stouffer, Z. Hu, M. Sajid, H. Li, G. Jin, M. T. Nakada, S. R. Hanson, and M. S. Runge ß3 Integrins Are Upregulated After Vascular Injury and Modulate Thrombospondin- and Thrombin-Induced Proliferation of Cultured Smooth Muscle Cells Circulation, March 10, 1998; 97(9): 907 - 915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pakala, J. T. Willerson, and C. R. Benedict Effect of Serotonin, Thromboxane A2, and Specific Receptor Antagonists on Vascular Smooth Muscle Cell Proliferation Circulation, October 7, 1997; 96(7): 2280 - 2286. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. D. Kugelmass and G. E. Raskob Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty or Coronary Stent Placement Clinical and Applied Thrombosis/Hemostasis, October 1, 1997; 3(1_suppl): S24 - S31. [PDF]
|
|
|
|
 |
|
 E. J. Topol, J. J. Ferguson, H. F. Weisman, J. E. Tcheng, S. G. Ellis, N. S. Kleiman, R. J. Ivanhoe, A. L. Wang, D. P. Miller, K. M. Anderson, et al. Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin {beta}3 Blockade With Percutaneous Coronary Intervention JAMA, August 13, 1997; 278(6): 479 - 484. [Abstract] [PDF]
|
|
|
|
|
|
K. G. Lehmann, R. Melkert, and P. W. Serruys Contributions of Frequency Distribution Analysis to the Understanding of Coronary Restenosis : A Reappraisal of the Gaussian Curve Circulation, March 15, 1996; 93(6): 1123 - 1132. [Abstract] [Full Text]
|
|
|
|
|
|
A. G. Violaris, R. Melkert, J.-P. R. Herrman, and P. W. Serruys Role of Angiographically Identifiable Thrombus on Long-term Luminal Renarrowing After Coronary Angioplasty : A Quantitative Angiographic Analysis Circulation, March 1, 1996; 93(5): 889 - 897. [Abstract] [Full Text]
|
|
|
|
|
|
S. G. Ellis, N. Omoigui, J. A. Bittl, M. Lincoff, M. W. Wolfe, G. Howell, and E. J. Topol Analysis and Comparison of Operator-Specific Outcomes in Interventional Cardiology : From a Multicenter Database of 4860 Quality-Controlled Procedures Circulation, February 1, 1996; 93(3): 431 - 439. [Abstract] [Full Text]
|
|
|
|
|
|
D. Zahger, M. C. Fishbein, L. I. Garfinkel, P. K. Shah, J. S. Forrester, J. Regnstrom, J. Yano, and B. Cercek VCL, an Antagonist of the Platelet GP1b Receptor, Markedly Inhibits Platelet Adhesion and Intimal Thickening After Balloon Injury in the Rat Circulation, September 1, 1995; 92(5): 1269 - 1273. [Abstract] [Full Text]
|
|
|
|
|
|
A. G. Violaris, R. Melkert, and P. W. Serruys Long-term Luminal Renarrowing After Successful Elective Coronary Angioplasty of Total Occlusions : A Quantitative Angiographic Analysis Circulation, April 15, 1995; 91(8): 2140 - 2150. [Abstract] [Full Text]
|
|
|
|
|
|
D. Keane, J. Haase, C. J. Slager, E. M. van Swijndregt, K. G. Lehmann, Y. Ozaki, C. di Mario, R. Kirkeeide, and P. W. Serruys Comparative Validation of Quantitative Coronary Angiography Systems : Results and Implications From a Multicenter Study Using a Standardized Approach Circulation, April 15, 1995; 91(8): 2174 - 2183. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Tousoulis, G. Davies, P. Toutouzas, and P. Golino Intracoronary Ketanserin after Coronary Angioplasty N. Engl. J. Med., July 14, 1994; 331(2): 130 - 131. [Full Text]
|
|